The anti-asthma TDM assay kits market is anticipated to grow at a CAGR of 4.5% during the forecast period with a valuation of US$ 18 Bn in 2022.
Sales of anti-asthma TDM assay kits are expected to rise as the global prevalence of asthma is also on a sharp rise. In addition to this, demand for anti-asthma TDM assay kits is rising in developing countries that are now experiencing a sudden rise in pollution levels, leading to more severe asthmatic conditions.
| Attributes | Details |
| Anti-asthma TDM Assay Kits CAGR | 4.5% |
| Anti-asthma TDM Assay Kits (2022) | US$ 18 Bn |
Increasing life expectancies have also increased the risk for asthma, which is projected to contribute to the anti-asthma TDM assay kits market share.
The report sheds light on the factors improving the sales of anti-asthma TDM assay kits and, in turn, the opportunities for the market players. However, the anti-asthma TDM assay kits market also faces some challenges, limiting the anti-asthma TDM assay kits market share from reaching its potential.
Some of the key anti-asthma TDM assay kits market trends promoting the demand for anti-asthma TDM assay kits include an increase in the geriatric population as well as improvement in medical facilities.
The anti-asthma TDM assay kits market is expected to grow faster because of the increased tendency of patients to perform anti-asthma TDM assay in case of asthma. The demand for anti-asthma TDM assay kits is also growing because of the need to adjust the dose per individual’s need & to minimize the risk of dose-related toxicity in asthmatic patients.
Physicians selectively use Anti-asthma TDM assay kits because of their optimum sensitivity, accuracy, excellent correlation to reference methods, and dynamic range to monitor the drug levels. Owing to an improved understanding of anti-asthmatic pharmacology, pharmacokinetics, and pharmacodynamics, the sales of anti-asthma TDM assay kits are becoming a more valuable adjunct to routine assays because of advanced technological developments.
According to the World Health Organization, around 235 million people had asthma in the year 2017. Anti-asthma TDM assay kits market is anticipated to boost furthermore because of an increase in the number of asthmatic patients.
Therapeutic drug monitoring is mainly used for compounds whose pharmacological effects cannot be easily determined. TDM measures the plasma concentration of the drug in the given therapy. TDM involves not only measuring drug concentration but also the clinical interpretation of results. It also helps to increase efficacy, decrease toxicity, and to assist in diagnosis.
Tobacco smoking is highly related to the increased risk of asthma. Also, the children of parents who have the habit of smoking are at high risk of being asthmatic. This factor is anticipated to drive the anti-asthma TDM assay kits market in upcoming years. Many clinical laboratories approaching TDM assay as a quick evolving technique in asthmatic patients can also be the driving factor for the anti-asthma TDM assay kits market.
Physicians’ increased preference for TDM assays and patients’ increased self-awareness for controlling asthma is expected to be the factors propelling the growth of sales of anti-asthma TDM assay kits in the global industry.
The increase in the prevalence and incidence of extrinsic & intrinsic asthma creates opportunities for manufacturers in this market. The global sales of anti-asthma TDM assay kits are forecasted to experience substantial growth in the upcoming years. There are more opportunities in low & lower-middle-income countries, where most asthma deaths have been reported.
Asthma is an extensively predominant disease in people over age 65. The global population is owed to increased life expectancies. Hence, an increase in the geriatric population is associated with increasing demand for anti-asthma TDM assay kits which can also be considered to be the driving factor for the rise in demand for anti-asthma TDM assay kits.
Geographically, theanti-asthma TDM assay kits market is segmented into regions viz. North America, Europe, Asia Pacific, South America, Middle East & Africa. North America is expected to be the leading the sales of anti-asthma TDM assay kits, followed by Europe & Asia Pacific.
Developing countries, especially Asia Pacific countries, are forecasted to grow at a faster rate in this market because of developing healthcare facilities. According to WHO, most asthma-related deaths occur in low & lower-middle-income countries. Hence there are better opportunities in such regions with high demand for anti-asthma TDM assay kits.
Some of the global key participants in the anti-asthma TDM assay kits market responsible for the highsales of anti-asthma TDM assay kits include F. Hoffmann-La Roche AG, Bio-Techne Corporation, Svar Life Science AB, Thermo Fisher Scientific Inc., Eagle Biosciences Inc, Merck KGaA, Elabsciance, Creative Diagnostics, MyBioSource, Inc., Diagnostic Automation/Cortez Diagnostics, Inc, and many others.
The report consists of key players contributing to the anti-asthma TDM assay kits market share. It also consists of organic and inorganic growth strategies adopted by market players to improve their market positions. This exclusive report analyzes the competitive landscape and anti-asthma TDM assay kits market share acquired by players to strengthen their market position.
| Report Attribute | Details |
| Base year for estimation | 2021 |
| Historical data | 2015 - 2020 |
| Forecast period | 2022 - 2032 |
| Quantitative units | Revenue in USD billion, volume in kilotons, and CAGR from 2022 to 2032 |
| Report coverage | Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis |
| Segments covered | Product, Assay, End User, Region |
| Regional scope | North America; Western Europe, Eastern Europe, Middle East, Africa, ASEAN, South Asia, Rest of Asia, Australia and New Zealand |
| Country scope | U.S.; Canada; Mexico; Germany; U.K.; France; Italy; Spain; Russia; Belgium; Poland; Czech Republic; China; India; Japan; Australia; Brazil; Argentina; Colombia; Saudi Arabia; UAE; Iran; South Africa |
| Key companies profiled | F. Hoffmann-La Roche AG, Bio-Techne Corporation, Svar Life Science AB, Thermo Fisher Scientific Inc., Eagle Biosciences Inc, Merck KGaA, Elabsciance, Creative Diagnostics, MyBioSource, Inc., Diagnostic Automation/Cortez Diagnostics, Inc and many others. |
| Customization scope | Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. |
Key players holding substantial anti-asthma TDM assay kits market share include F. Hoffmann-La Roche AG, Bio-Techne Corporation, Svar Life Science AB, Thermo Fisher Scientific Inc., Eagle Biosciences Inc, Merck KGaA, Elabsciance, Creative Diagnostics, MyBioSource, Inc., Diagnostic Automation/Cortez Diagnostics, Inc. and many others.
Demand for anti-asthma TDM assay kits is likely to rise on the back of increasing geriatric population.
The anti-asthma TDM assay kits market is estimated to record a CAGR of 4.5% during the forecast period.
Explore Similar Insights
Anti-Asthma TDM Assay Kits Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
